Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 901–950 of 1,359 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT02971410	Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory…	Early Phase 1	withdrawn	Nov 23, 2016	Wake Forest University Health Sciences	PI no longer interested in pursuing study.	Other (stated, no rule matched)
NCT01050764	Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells	Phase 1 / Phase 2	terminated	Jan 15, 2010	Everett Meyer	Safety	Safety / toxicity
NCT02419469	Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute…	Phase 2	terminated	Apr 17, 2015	M.D. Anderson Cancer Center	Slow Accrual	Enrollment / accrual
NCT00664378	Efficacy Study of CYT997 in Multiple Myeloma	Phase 2	terminated	Apr 22, 2008	Gilead Sciences	Difficulty enrolling patients	Enrollment / accrual
NCT00538824	Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed…(DexTR)	Phase 2	terminated	Oct 3, 2007	Weill Medical College of Cornell University	low enrollment	Enrollment / accrual
NCT01326728	Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation	—	terminated	Mar 31, 2011	National Cancer Institute (NCI)	A replacement protocol was created to replace this current version of protocol.	Other (stated, no rule matched)
NCT01812005	Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory…	Phase 2	terminated	Mar 15, 2013	Ohio State University Comprehensive Cancer Center	Slow patient enrollment and study discontinued after 14 patients enrolled	Enrollment / accrual
NCT01979276	Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma(Romi Poma)	Phase 1 / Phase 2	terminated	Nov 8, 2013	Weill Medical College of Cornell University	this study was terminated due to losing financial support, and enrollment challenges	Enrollment / accrual
NCT02420210	Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell…	Phase 2	terminated	Apr 17, 2015	University of Chicago	Trials was stopped early due to lack of funding.	Funding
NCT01174082	Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma…	Phase 2	terminated	Aug 3, 2010	M.D. Anderson Cancer Center	Slow Accrual	Enrollment / accrual
NCT03023527	Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma	Phase 1	terminated	Jan 18, 2017	PETHEMA Foundation	Safety	Safety / toxicity
NCT01200589	Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin…(HOMER)	Phase 3	terminated	Sep 13, 2010	Novartis Pharmaceuticals	The study stopped due to futility.	Efficacy / futility
NCT00482053	Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation…	Phase 2	terminated	Jun 4, 2007	Stanford University	Low accrual	Enrollment / accrual
NCT02985333	Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma	Phase 2	withdrawn	Dec 7, 2016	Sun Yat-sen University	not stated	Not stated
NCT02372240	A Study of VLX1570 and Dexamethasone in Myeloma Patients	Phase 1 / Phase 2	terminated	Feb 26, 2015	Vivolux AB	Dose limiting tox is observed. Study put on full clinical hold.	Other (stated, no rule matched)
NCT02359162	Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat…	Phase 3	terminated	Feb 9, 2015	Sun Yat-sen University	The study is out of date	Other (stated, no rule matched)
NCT02533323	P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens	Phase 2	terminated	Aug 26, 2015	Sun Yat-sen University	not stated	Not stated
NCT00290407	Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic…	Phase 2	terminated	Feb 13, 2006	University of Louisville	terminated due to lack of accrual	Enrollment / accrual
NCT00984165	Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic…	Phase 2	terminated	Sep 25, 2009	National Cancer Institute (NCI)	Terminated due to slow accrual, PI left NIH and primary endpoint not met.	Investigator
NCT02877082	Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood…	Phase 2	terminated	Aug 24, 2016	Emory University	not stated	Not stated
NCT00626626	Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation	Phase 1 / Phase 2	terminated	Feb 29, 2008	Milton S. Hershey Medical Center	Investigator decision	Investigator
NCT01382615	Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research	—	terminated	Jun 27, 2011	Dartmouth-Hitchcock Medical Center	Unable to fill cohort	Other (stated, no rule matched)
NCT02155634	Continuous Lenalidomide Therapy Versus Observation Following Induction Without…	Phase 3	withdrawn	Jun 4, 2014	Celgene	The study was terminated due to poor feasibility and lack of interest at the participating sites.	Other (stated, no rule matched)
NCT02732925	To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in…(MELODY)	N/A	terminated	Apr 11, 2016	Royal National Orthopaedic Hospital NHS Trust	Difficulties with recruitment due to change in referral rates.	Enrollment / accrual
NCT03369964	A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or…	Phase 1	withdrawn	Dec 12, 2017	Hoffmann-La Roche	Business decision: no safety or efficacy concerns.	Safety / toxicity
NCT00909948	Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following…(RLI)	Phase 1	terminated	May 29, 2009	Massachusetts General Hospital	Slow Accrual	Enrollment / accrual
NCT02488512	Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse…(itTRIOlym)	Phase 2	terminated	Jul 2, 2015	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	critical low recruitment rate	Enrollment / accrual
NCT02530125	Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma…	Phase 2	terminated	Aug 20, 2015	Northwestern University	sponsor decided to discontinue development of the study drug.	Sponsor / business decision
NCT00113646	Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for…	Phase 2	terminated	Jun 10, 2005	Massachusetts General Hospital	Expiration of MEDI-507	Other (stated, no rule matched)
NCT00113828	Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for…	Phase 2	terminated	Jun 13, 2005	Massachusetts General Hospital	Insufficient accrual	Enrollment / accrual
NCT03235869	Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma	Early Phase 1	withdrawn	Aug 1, 2017	University of Michigan Rogel Cancer Center	The company pulled durvalumab from heme malignancies	Sponsor / business decision
NCT00354107	Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent…	Phase 1 / Phase 2	terminated	Jul 20, 2006	National Cancer Institute (NCI)	not stated	Not stated
NCT02366663	BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL(SPINOZA)	Phase 3	terminated	Feb 19, 2015	City of Hope Medical Center	Withdrawal of sponsor support	Other (stated, no rule matched)
NCT01313611	BRIEF Bendamustine and Rituximab In Elderly Follicular(BRIEF)	Phase 2	terminated	Mar 14, 2011	The Lymphoma Academic Research Organisation	Treament with rituximab during maintenance phase was stoped, according to DSMC recommendations,…	Other (stated, no rule matched)
NCT01147393	Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular…	Phase 1 / Phase 2	terminated	Jun 22, 2010	Weill Medical College of Cornell University	closed to enrollment due to slow patient accrual	Enrollment / accrual
NCT00588263	Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish…	—	withdrawn	Jan 8, 2008	Memorial Sloan Kettering Cancer Center	Data from MSK-IMPACT is sufficient for relevant analyses going forward	Other (stated, no rule matched)
NCT02578511	Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With…	Phase 1	withdrawn	Oct 19, 2015	Ehab L Atallah	No enrollment, another competing study and difficult to find the right person to enroll on this…	Enrollment / accrual
NCT00481832	Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's…	Phase 2	terminated	Jun 4, 2007	Stanford University	Accrual Factor	Enrollment / accrual
NCT01002248	Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple…	Phase 3	terminated	Oct 27, 2009	AEterna Zentaris	not stated	Not stated
NCT01315873	Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma	Phase 2	terminated	Mar 15, 2011	NYU Langone Health	PI left the institution before all data analysis was completed	Investigator
NCT00003500	Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV…	Phase 2	terminated	Jan 27, 2003	Burzynski Research Institute	slow accrual	Enrollment / accrual
NCT00003501	Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV…	Phase 2	terminated	Jan 27, 2003	Burzynski Research Institute	slow accrual	Enrollment / accrual
NCT00003512	Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's…	Phase 2	withdrawn	Jan 27, 2003	Burzynski Research Institute	No participants enrolled	Enrollment / accrual
NCT01675141	Lenalidomide Maintenance Therapy for Multiple Myeloma	Phase 2	terminated	Aug 29, 2012	National Cancer Institute (NCI)	Original investigator left the NIH and the primary outcome was not reached	Investigator
NCT01446900	R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia…	Phase 2	terminated	Oct 5, 2011	European Institute of Oncology	low rate in patient accrual	Enrollment / accrual
NCT02983097	Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa,…(R²-DHAP)	Phase 1 / Phase 2	terminated	Dec 6, 2016	Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH	Phase II: no scientific interests are given anymore	Other (stated, no rule matched)
NCT00455897	CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large…	Phase 2	terminated	Apr 4, 2007	Massachusetts General Hospital	Accrual was too slow. Trial terminated	Enrollment / accrual
NCT01929941	An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced…	Phase 1	terminated	Aug 28, 2013	Incyte Corporation	Business decision.	Sponsor / business decision
NCT03205891	Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin…	Phase 1	withdrawn	Jul 2, 2017	M.D. Anderson Cancer Center	Change in treatment priorities for these disease types as well as staffing concerns.	Other (stated, no rule matched)
NCT02200848	Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic…	Phase 1	terminated	Jul 25, 2014	Georgetown University	Recruitment difficulties and toxicity	Safety / toxicity

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Jul 2, 2018source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules